3.8 Article

Safety of measles, mumps, and rubella vaccine in adolescents and adults in the vaccine safety Datalink

Related references

Note: Only part of the references are listed.
Article Immunology

Monitoring vaccine safety using the vaccine safety Datalink: Assessing capacity to integrate data from Immunization Information systems

Holly C. Groom et al.

Summary: This study investigated the data receiving and integration status of eight Vaccine Safety Datalink (VSD) sites, and found that COVID-19 vaccine data can be timely received and integrated, which lays a solid foundation for vaccine safety quality assessments within the VSD.

VACCINE (2022)

Review Biotechnology & Applied Microbiology

Use of M-M-R II outside of the routinely recommended age range - a systematic literature review

Manjiri Pawaskar et al.

Summary: The M-M-R II vaccine demonstrates good immunogenicity and safety in individuals aged 6-11 months and >= 7 years, with high seroconversion rates for measles, mumps, and rubella. Adverse events are generally mild and well tolerated in older age groups. Efficacy studies are lacking, but evidence from randomized controlled trials supports the use of M-M-R II in individuals >= 7 years of age.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

Article Immunology

Adverse Events Among Young Adults Following a Third Dose of Measles-Mumps-Rubella Vaccine

Mona Marin et al.

Summary: The research found that the reported adverse events in young adults receiving a third measles-mumps-rubella (MMR) vaccine (MMR3) in a non-outbreak setting were mild and transient, indicating that MMR3 is safe and tolerable in this population.

CLINICAL INFECTIOUS DISEASES (2021)

Article Immunology

Evaluation of the Safety and Immunogenicity of M-M-RII (Combination Measles-mumps-rubella Vaccine) Clinical Trials of Healthy Children and Adults Published Between 2010 and 2019

Mawuli Nyaku et al.

Summary: In clinical trials from 2010 to 2019, M-M-RII vaccine continued to demonstrate safety and good immunogenicity in all age groups studied, maintaining consistent performance over more than 30 years of postlicensure studies.

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2021)

Article Computer Science, Interdisciplinary Applications

The REDCap consortium: Building an international community of software platform partners

Paul A. Harris et al.

JOURNAL OF BIOMEDICAL INFORMATICS (2019)

Article Pediatrics

Safety of Measles-Containing Vaccines in 1-Year-Old Children

Nicola P. Klein et al.

PEDIATRICS (2015)

Article Computer Science, Interdisciplinary Applications

Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support

Paul A. Harris et al.

JOURNAL OF BIOMEDICAL INFORMATICS (2009)

Article Medicine, General & Internal

The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine

WE Barlow et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)